Market Research Report
Epiomic Epidemiology Series: Primary Immunodeficiency Diseases Forecast in 23 Major Markets 2018-2028
|Published by||Black Swan Analysis||Product code||355843|
|Published||Content info||66 Pages
Delivery time: 1-2 business days
|Epiomic Epidemiology Series: Primary Immunodeficiency Diseases Forecast in 23 Major Markets 2018-2028|
|Published: September 1, 2018||Content info: 66 Pages||
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Primary Immunodeficiency Diseases in 23 Major Markets
Primary immunodeficiency diseases (PID) are a group of inherited genetic disorders of the genes governing the immune system. PIDs are a group of more than 200 rare, chronic disorders in which part of the body's immune system is missing or functions improperly. Some types of PID affect a single part of the immune system while others may affect one or more components of the system. The result is a compensatory, often exaggerated and chronic inflammatory response by less effective alternative immune pathways, which damage not only infected cells but also surrounding tissue.
This report provides the current prevalent population for PID across 23 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Sweden, Austria, Switzerland, Greece, Czech Republic, Hungary, Turkey, Japan, China, India, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, PID patients grouped by disease classification have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Ability to quantify patient populations in global PID market to target the development of future products, pricing strategies and launch plans.
Further insight into the prevalence of the subdivided types of PID and identification of patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Identification of PID patient sub-populations that require treatment.
Better understanding of the specific markets that have the largest number of PID patients.